Jefferies 2024 – Cargo tries again with an old idea
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
Scancell’s dilemma delayed
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
No PRAME encore for Immatics
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
Genmab formalises the challenge against its partner
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
